<Suppliers Price>

Belantamab Mafodotin

Names

[ CAS No. ]:
2050232-20-5

[ Name ]:
Belantamab Mafodotin

Biological Activity

[Description]:

Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2]. Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2]. Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].

[In Vivo]

Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. Animal Model: Mice harbouring OPM2 tumours[2] Dosage: 4 mg/kg Administration: IP, twice weekly for 4 doses Result: Signifcantly improves survival compared to vehicle.

[References]

[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.  

[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds